-
1 Comment
aTyr Pharma, Inc is currently in a long term uptrend where the price is trading 12.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
aTyr Pharma, Inc's total revenue sank by 92.7% to $10K since the same quarter in the previous year.
Its net income has increased by 17.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 9.1% to $-5M since the same quarter in the previous year.
Based on the above factors, aTyr Pharma, Inc gets an overall score of 3/5.
| Sector | Financial Services |
|---|---|
| Industry | Insurance Brokers |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| ISIN | None |
| Market Cap | 637M |
|---|---|
| PE Ratio | 8.89 |
| Target Price | 20.25 |
| Beta | nan |
| Dividend Yield | None |
Ethos Technologies Inc. provides third-party administrator services for insurance policies in the United States. The company offers Ethos, a three-sided technology platform that serves an ecosystem of consumers, agents, and carriers. It also provides term life insurance, whole life insurance, and indexed universal life insurance products, as well as wills and estate planning, and supplemental health insurance products. The company was formerly known as Ethos Insurance Corporation and changed its name to Ethos Technologies Inc. in August 2016. The company was incorporated in 2016 and is based in San Francisco, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LIFE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
